1. Home
  2. News
  3. Imugene Ltd
  4. Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA
More Imugene Ltd news
Imugene LtdASX: IMU

Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA

Aug 31, 2022 at 11:52 PM EDT · Issued by Imugene Ltd

Filed with ASX · Aug 31, 2022 at 11:52 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/imugene-dose-escalates-in-phase-i-clinical-trial-of-vaxinia

Imugene Ltd on 6ix

Story so far

  • Imugene doses first patient in VAXINIA Phase 1 trialMay 18, 2022
  • Clinical Trial of New Cancer Oncolytic Virotherapy VaxiniaMar 23, 2022
  • First patient dosed in Phase I clinical trial of CHECKvaccOct 20, 2021

Earlier from Imugene

  • Annual Report and Appendix 4EAug 30, 2022
  • First cohort 3 patient dosed in clinical trial of CHECKvaccAug 9, 2022
  • Imugene Presents New PD1-Vaxx Data at the 2022 WCLCAug 7, 2022
  • Final HER-Vaxx Phase 2 Trial Overall Survival ResultsJun 26, 2022
  • Imugene doses first patient in VAXINIA Phase 1 trialMay 17, 2022

Later from Imugene

  • Imugene doses first patient in nextHERIZON Phase 2 trialSep 7, 2022
  • Imugene announces a$80 million institutional placementSep 12, 2022
  • Prospectus for the issue of institutional placement optionsSep 16, 2022
  • OGTR grants VAXINIA DIR licence allowing trial expansionSep 19, 2022
  • First patient IV dosed in VAXINIA Phase 1 clinical trialSep 20, 2022
All Imugene news releases↗

Follow Imugene into a list and get an email when it puts out news.

Follow Imugene
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer